Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and endocrine therapy vs paclitaxel in ER+ breast cancer
NCT02603679Phase 2Active, not recruiting
- Start
- Feb 2015
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib in estrogen receptor-positive breast cancer (ER+). Started Feb 2015; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT02603679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603679.